Fexofenadine Hydrochloride Tablets, USP 180 mg, Antihistamine, 150 Tablets per bottle, Distribute...
FDA Drug Recall #D-0654-2026 - Class III, June 1, 2026
Recall Summary
| Recall Number | D-0654-2026 |
| Classification | Class III, Low risk |
| Date Initiated | June 1, 2026 |
| Status | Ongoing |
| Voluntary | Voluntary: Firm initiated |
Recalling Firm
| Firm | SUN PHARMACEUTICAL INDUSTRIES INC |
| Location | Princeton, NJ |
| Product Type | Drugs |
| Quantity | 9,048 bottles |
Product Description
Fexofenadine Hydrochloride Tablets, USP 180 mg, Antihistamine, 150 Tablets per bottle, Distributed by: Ohm Laboratories, Inc., New Brunswick, NJ 08901. NDC 66336-561-30
Reason for Recall
Failed Impurities/Degradation Specifications
Distribution Pattern
U.S. Nationwide
Lot / Code Information
Lot, expiry: Lot DNG0283A, exp 03/31/2027; Lots DNF0922A and DNF0923B, exp 10/31/2026
Other Recalls from SUN PHARMACEUTICAL INDUSTRIES INC
| Recall # | Classification | Product | Date |
|---|---|---|---|
| D-0628-2026 | Class II | Perampanel CIII Tablets, 6mg, Rx only, 30 Table... | Jun 17, 2026 |
| D-0607-2026 | Class II | Budesonide Inhalation Suspension, 1mg/2mL, 30 x... | May 29, 2026 |
| D-0598-2026 | Class II | Xyvona (levorphanol tartrate tablets), 2mg, 100... | May 22, 2026 |
| D-0599-2026 | Class II | Xyvona (levorphanol tartrate tablets), 3mg, 100... | May 22, 2026 |
| D-0580-2026 | Class I | DOXOrubin Hydrochloride Liposome injection, 50 ... | May 12, 2026 |
Frequently Asked Questions
Nitrosamines are probable human carcinogens, they can increase cancer risk with long-term exposure above certain thresholds, but they do not cause immediate harm from taking a single dose. The FDA calculates an acceptable daily intake (ADI) for each nitrosamine compound, and recalls are triggered when levels exceed this threshold. If you have been taking a recalled product, the FDA generally advises against abruptly stopping your medication (especially for critical conditions like blood pressure or diabetes) until you consult your doctor. The incremental cancer risk from short-term exposure is very small.
Not necessarily. Many drug recalls are initiated because of quality system failures or test results that suggest a product might not meet specifications, even if no patients have reported harm. The FDA uses a precautionary approach: if there is reason to believe quality standards were not met, a recall is required regardless of whether adverse effects have been reported. Class I recalls typically involve a reasonable probability of harm; Class II recalls may cause temporary health issues; Class III recalls are for products unlikely to cause adverse health consequences but that still violate regulations.
Pharmacies typically receive recall notices directly from drug wholesalers and manufacturers within days of the recall being announced. Your pharmacist can look up whether any product in your prescription history matches a recalled lot number. For current recalls, the FDA publishes updates at FDA.gov/safety/recalls-market-withdrawals-safety-alerts and sends MedWatch email alerts for significant drug safety issues. You can sign up for MedWatch alerts at FDA.gov. Most major pharmacy chains also have their own recall notification systems that automatically alert pharmacists when a recalled product is in their inventory.
What Should You Do?
Stop using this medication if affected by this recall. Contact your pharmacist or prescribing doctor immediately for guidance. Do not flush medications, use a drug take-back program.